PMC:3724972 / 11574-11955 JSONTXT

{"project":"2_test","denotations":[{"id":"23673515-22397653-63233624","span":{"begin":350,"end":352},"obj":"22397653"}],"text":"Changes in UFC levels from baseline to 6 months in individual patients in the phase 3 trial of pasireotide. The dashed black line represents the upper limit of the normal range for UFC. From Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, et al., for the Pasireotide B2305 Study Group (2012) N Engl J Med, volume 366, page 918 [43]. Reproduced with permission"}